

# PUBLIC HEALTH SERVICE

## BIOLOGICAL MATERIALS LICENSE AGREEMENT

This **Agreement** is based on the model Biological Material License Agreement adopted by the U.S. Public Health Service (“**PHS**”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“**NIH**”), the Centers for Disease Control and Prevention (“**CDC**”), and the Food and Drug Administration (“**FDA**”), which are agencies of the **PHS** within the Department of Health and Human Services (“**HHS**”).

This Cover Page identifies the Parties to this **Agreement**:

The U.S. Department of Health and Human Services, as represented by

[Insert the full name of the IC]

an Institute or Center (hereinafter referred to as the “**IC**”) of the

[INSERT as appropriate: NIH, CDC, or FDA]

and

[Insert Company’s official name],

hereinafter referred to as the “**Licensee**”,

having offices at [Insert Company’s address],

created and operating under the laws of [Insert State of Incorporation].

**Tax ID No.:** \_\_\_\_\_

1. Definitions:

- (a) “**Government**” means the government of the United States of America.
- (b) “**FDA**” means the Food and Drug Administration.
- (c) “**Materials**” means the following biological materials including all progeny, subclones, and unmodified derivatives thereof:  
\_\_\_\_\_, as described in \_\_\_\_\_  
\_\_\_\_\_ and developed in the laboratory of \_\_\_\_\_ at the **IC**.
- (d) “**Licensed Field of Use**” means \_\_\_\_\_.
- (e) “**Licensed Products**” means \_\_\_\_\_.
- (f) “**Net Sales**” means the total gross receipts by the **Licensee** for sales of **Licensed Products** or from income from leasing, renting, or otherwise making **Licensed Products** available to others without sale or other dispositions transferring title, whether invoiced or not, less returns and allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted. No deductions shall be made for commissions paid to individuals, whether they are with independent sales agencies or regularly employed by the **Licensee**, or for the cost of collections.

2. The **Licensee** desires to obtain a license from the **IC** to use the **Materials** provided under this **Agreement** in its commercial research or product development and marketing activities. The **Licensee** represents that it has the facilities, personnel, and expertise to use the **Materials** or the **Licensed Products** for commercial purposes and agrees to expend reasonable efforts and resources to develop the **Materials** or the **Licensed Products** for commercial use or commercial research.

3. The **IC** hereby grants to the **Licensee**:

- (a) a worldwide, non-exclusive license to make, have made, and use the **Materials** or the **Licensed Products** in the **Licensed Field of Use**; and
- (b) a worldwide, non-exclusive license to sell and have sold, to offer to sell and to import the **Licensed Products** in the **Licensed Field of Use**.

4. In consideration of the grant in Paragraph 3, the **Licensee** hereby agrees to make the following payments to the **IC**:

- (a) Within sixty (60) days of its execution of this **Agreement**, a noncreditable, nonrefundable license issue royalty of \_\_\_\_\_ dollars (\$X).
- (b) The first minimum annual royalty of \_\_\_\_\_ dollars (\$XX) is due within sixty (60) days of the effective date of this **Agreement** and may be prorated according to the fraction of the calendar year remaining between the effective date of this **Agreement** and the next subsequent January 1;

- (c) Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year;
  - (d) An earned royalty of \_\_\_\_\_ percent (X%) of **Net Sales**, which shall be due and payable within sixty (60) days of the end of each calendar year; and
  - (e) All payments required under this **Agreement** shall be paid in U.S. dollars and payment options are listed in Appendix C. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in *The Wall Street Journal* on the day that the payment is due.
    - i) Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the **Licensee**; and
    - ii) Additional royalties may be assessed by the **IC** on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the **IC** of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent the **IC** from exercising any other rights it may have as a consequence of the lateness of any payment.
5. Upon receipt by the **IC** of the license issue royalty and the prorated first year minimum annual royalty and verification of these royalties, the **IC** agrees to provide the **Licensee** with samples of the **Materials**, as available, and to replace these **Materials**, as available, at reasonable cost, in the event of their unintentional destruction. The **IC** shall provide the **Materials** to the **Licensee** at the **Licensee's** expense and as specified in Appendix A.
6. The **Licensee** agrees to make written reports to the **IC** within sixty (60) days of December 31 for each calendar year. This report shall state: the number, description, and aggregate **Net Sales** of **Licensed Products** made, sold, or otherwise disposed of; the total gross income received by the **Licensee** from leasing, renting, or otherwise making **Licensed Products** available to others without sale or other disposition transferring title, during the calendar year; and the resulting calculation of earned royalties due to the **IC** pursuant to Paragraph 4(d) and as shown in the example in Appendix B. The **Licensee** shall submit each report to the **IC** at the Mailing Address for **Agreement** notices indicated on the Signature Page.
7. The **Licensee** agrees to supply the laboratory of Dr. \_\_\_\_\_ at the **IC** at no charge, reasonable quantities of **Materials** or the **Licensed Products** that the **Licensee** makes, uses, sells, or offers for sale or otherwise makes available for public use. The **Licensee** also agrees to supply, to the Mailing Address for **Agreement** notices indicated on the Signature Page, the Office of Technology Transfer, **NIH** with inert samples of the **Licensed Products** or their packaging for educational and display purposes only.
8. This **Agreement** shall become effective on the date when the last party to sign has executed this **Agreement**, unless the provisions of Paragraph 26 are not fulfilled, and shall expire \_\_\_\_\_ (X) years from this effective date, unless previously terminated under the terms of Paragraphs 16 or 17.
9. As part of the **Licensee's** performance under this **Agreement**, the **Licensee** agrees to make the **Licensed Products** available to the public within \_\_\_\_\_ (X) months from the effective date of this **Agreement**.

A-XXX-201X

**CONFIDENTIAL**

10. The **Licensee** agrees to retain control over the **Materials** and the **Licensed Products**, and not to distribute them to third parties without the prior written consent of the **IC** except as provided in Paragraph 3.
11. This **Agreement** does not preclude the **IC** from distributing the **Materials** or the **Licensed Products** to third parties for research or commercial purposes.
12. By this **Agreement**, the **IC** grants no patent rights expressly or by implication to any anticipated or pending **IC** patent applications or issued patents.
13. NO WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED AS TO THE MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF THE **MATERIALS** PROVIDED TO THE **LICENSEE** UNDER THIS **AGREEMENT**, OR THAT THE **MATERIALS** OR THE **LICENSED PRODUCTS** MAY BE EXPLOITED WITHOUT INFRINGING THE PATENT RIGHTS OF ANY THIRD PARTIES. The **Licensee** accepts license rights to the **Materials** and the **Licensed Products** “as is”, and the **IC** does not offer any guarantee of any kind.
14. **Licensee** agrees to indemnify and hold harmless the **Government** from any claims, costs, damages, or losses that may arise from or through the **Licensee's** use of the **Materials** or the **Licensed Products**. The **Licensee** further agrees that it shall not by its action bring the **Government** into any lawsuit involving the **Materials** or the **Licensed Products**.
15. The **Licensee** agrees in its use of the **Materials** or the **Licensed Products** to comply with all applicable statutes, regulations, and guidelines, including **NIH** and **HHS** regulations and guidelines. The **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials in the United States without complying with [21 C.F.R. Part 50](#) and [45 C.F.R. Part 46](#). The **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials outside of the United States without notifying the **IC**, in writing, of such research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the **IC** of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of such research or trials.
16. The **Licensee** may terminate this **Agreement** upon thirty (30) days written notice to the **IC** but only after sixty (60) days from the effective date of this **Agreement**.
17. The **IC** may terminate this **Agreement** if the **Licensee** is in default in the performance of any material obligation under this **Agreement**, and if the default has not been remedied within ninety (90) days after the date of written notice by the **IC** of the default.
18. Within thirty (30) days of the termination or expiration of this **Agreement**, the **Licensee** agrees to return all **Materials** and the **Licensed Products** to the **IC** or provide the **IC** with written certification of their destruction.
19. Within ninety (90) days of termination or expiration of this **Agreement**, the **Licensee** agrees to submit a final report to the **IC**, and to submit to the **IC** payment of any royalties due. The **Licensee** may not be granted additional **IC** licenses if this final reporting requirement is not fulfilled.
20. The **Licensee** is encouraged to publish the results of its research projects using the **Materials** or the **Licensed Products**. In all oral presentations or written publications concerning the **Materials** or the **Licensed Products**, the **Licensee** shall acknowledge the contribution of Dr. \_\_\_\_\_ at the **IC** supplying the **Materials**, unless requested otherwise by the **IC** or Dr. \_\_\_\_\_.

A-XXX-201X

**CONFIDENTIAL**

NIH Biological Materials License Agreement (BMLA)  
Model 10-2015 (updated 8-2012) Page 4 of 12 [Draft/Final] [Company] [Date]

21. All plans and reports required by this **Agreement** shall be treated by the **IC** as commercial and financial information obtained from a person and as privileged and confidential and, to the extent permitted by law, not subject to disclosure under the Freedom of Information Act, [5 U.S.C. §552](#)
22. This **Agreement** shall be construed in accordance with U.S. Federal law, as interpreted and applied by the U.S. Federal courts in the District of Columbia. Federal law and regulations shall preempt any conflicting or inconsistent provisions in this **Agreement**. The **Licensee** agrees to be subject to the jurisdiction of U.S. courts.
23. This **Agreement** constitutes the entire understanding of the **IC** and the **Licensee** and supersedes all prior agreements and understandings with respect to the **Materials** or the **Licensed Products**.
24. The provisions of this **Agreement** are severable, and in the event that any provision of the **Agreement** shall be determined to be invalid or unenforceable under any controlling body of law, the invalidity or unenforceability of any provision of this **Agreement**, shall not in any way affect the validity or enforceability of the remaining provisions of this **Agreement**.
25. Paragraphs 4, 13, 14, 18, 19, 20, 21 and 25 of this **Agreement** shall survive termination or expiration of this **Agreement**.
26. The terms and conditions of this **Agreement** shall, at the **IC's** sole option, be considered by the **IC** to be withdrawn from the **Licensee's** consideration and the terms and conditions of this **Agreement**, and the **Agreement** itself to be null and void, unless this **Agreement** is executed by the **Licensee** and a fully executed original is received by the **IC** within sixty (60) days from the date of the **IC** signature found at the Signature Page.

**SIGNATURES BEGIN ON NEXT PAGE**

A-XXX-201X

**CONFIDENTIAL**

NIH Biological Materials License Agreement (BMLA)

Model 10-2015 (updated 8-2012) Page 5 of 12 [Draft/Final] [Company] [Date]

THE IC BIOLOGICAL MATERIALS LICENSE AGREEMENT

SIGNATURE PAGE

In Witness Whereof, the parties have executed this **Agreement** on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below.

For the **IC**:

\_\_\_\_\_ **DRAFT** \_\_\_\_\_  
Name \_\_\_\_\_ Date \_\_\_\_\_  
Title \_\_\_\_\_  
Office \_\_\_\_\_  
National Institutes of Health

Mailing Address or E-mail Address for **Agreement** notices and reports:

License Compliance and Administration  
Monitoring & Enforcement  
Office of Technology Transfer  
National Institutes of Health  
6011 Executive Boulevard, Suite 325  
Rockville, Maryland 20852-3804 U.S.A.

E-mail: [LicenseNotices\\_Reports@mail.nih.gov](mailto:LicenseNotices_Reports@mail.nih.gov)

For the **Licensee** (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the **Licensee** made or referred to in this document are truthful and accurate.):  
by:

\_\_\_\_\_ **DRAFT** \_\_\_\_\_  
Signature of Authorized Official \_\_\_\_\_ Date \_\_\_\_\_

\_\_\_\_\_  
Printed Name

\_\_\_\_\_  
Title

I. Official and Mailing Address for **Agreement** notices:

\_\_\_\_\_  
Name

\_\_\_\_\_  
Title

Mailing Address

A-XXX-201X

**CONFIDENTIAL**

NIH Biological Materials License Agreement (BMLA)  
Model 10-2015 (updated 8-2012) Page 6 of 12 [Draft/Final] [Company] [Date]

---

---

---

---

Email Address: \_\_\_\_\_

Phone: \_\_\_\_\_

Fax: \_\_\_\_\_

II. Official and Mailing Address for Financial notices (the **Licensee's** contact person for royalty payments)

\_\_\_\_\_  
Name

\_\_\_\_\_  
Title

Mailing Address:  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Email Address: \_\_\_\_\_

Phone: \_\_\_\_\_

Fax: \_\_\_\_\_

Any false or misleading statements made, presented, or submitted to the **Government**, including any relevant omissions, under this **Agreement** and during the course of negotiation of this **Agreement** are subject to all applicable civil and criminal statutes including Federal statutes [31 U.S.C. §§3801-3812](#) (civil liability) and [18 U.S.C. §1001](#) (criminal liability including fine(s) and/or imprisonment).





## APPENDIX B – EXAMPLE ROYALTY REPORT

### Required royalty report information includes:

- License reference number (L-XXX-200X/0)
- Reporting period
- Catalog number and units sold of each Licensed Product (domestic and foreign)
- Gross Sales per catalog number per country
- Total Gross Sales
- Itemized deductions from Gross Sales
- Total Net Sales
- Earned Royalty Rate and associated calculations
- Gross Earned Royalty
- Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made
- Net Earned Royalty due

### Example

Catalog Number	Product Name	Country	Units Sold	Gross Sales (US\$)
1	A	US	250	62,500
1	A	UK	32	16,500
1	A	France	25	15,625
2	B	US	0	0
3	C	US	57	57,125
4	D	US	12	1,500

Total Gross Sales	153,250
Less Deductions:	
Freight	3,000
Returns	7,000
Total Net Sales	143,250
Royalty Rate	8%
Royalty Due	11,460
Less Creditable Payments	10,000
<b>Net Royalty Due</b>	<b>1,460</b>

A-XXX-201X

### CONFIDENTIAL

NIH Biological Materials License Agreement (BMLA)

Model 10-2015 (updated 8-2012) Page 9 of 12 [Draft/Final] [Company] [Date]

## APPENDIX C – ROYALTY PAYMENT OPTIONS

New Payment Options Effective March 2018

**The License Number MUST appear on payments, reports and correspondence.**

**Credit and Debit Card Payments:** Credit and debit card payments can be submitted for amounts up to \$24,999.

Submit your payment through the U.S. Treasury web site located at:

<https://www.pay.gov/public/form/start/28680443>.

### **Automated Clearing House (ACH) for payments through U.S. banks only**

The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at:

<https://www.pay.gov/public/form/start/28680443>. Please note that the IC "only" accepts ACH payments through this U.S. Treasury web site.

**Electronic Funds Wire Transfers:** The following account information is provided for wire payments.

In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a **U.S. bank account** via FEDWIRE:

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the **NIH ROYALTY FUND**.

Fedwire Field Tag	Fedwire Field Name	Required Information
{1510}	Type/Subtype	<b>1000</b>
{2000}	Amount	<i>(enter payment amount)</i>
{3400}	Receiver ABA routing number*	<b>021030004</b>
{3400}	Receiver ABA short name	<b>TREAS NYC</b>
{3600}	Business Function Code	<b>CTR (or CTP)</b>
{4200}	Beneficiary Identifier (account number)	<i>(enter 12 digit gateway account #)</i> <b>875080031006</b>
{4200}	Beneficiary Name	<i>(enter agency name associated with the Beneficiary Identifier)</i> <b>DHHS / NIH (75080031)</b>
{5000}	Originator	<i>(enter the name of the originator of the payment)</i> <b>COMPANY NAME</b>
{6000}	Originator to Beneficiary Information – Line 1	<i>(enter information to identify the purpose of the payment)</i> <b>ROYALTY</b>
{6000}	Originator to Beneficiary Information – Line 2	<i>(enter information to identify the purpose of the payment)</i> <b>LICENSE NUMBER</b>
{6000}	Originator to Beneficiary Information – Line 3	<i>(enter information to identify the purpose of the payment)</i> <b>INVOICE NUMBER</b>
{6000}	Originator to Beneficiary Information – Line 4	<i>(enter information to identify the purpose of the payment)</i>
Notes:		

A-XXX-201X

**CONFIDENTIAL**

NIH Biological Materials License Agreement (BMLA)

Model 10-2015 (updated 8-2012) Page 10 of 12 [Draft/Final] [Company] [Date]

Fedwire Field Tag	Fedwire Field Name	Required Information
*The financial institution address for Treasury's routing number is <u>33 Liberty Street, New York, NY 10045</u> .		

**Agency Contacts:** Office of Technology Transfer (OTT) (301) 496-7057 [OTT-Royalties@mail.nih.gov](mailto:OTT-Royalties@mail.nih.gov)

Drawn on a **foreign bank account** via FEDWIRE:

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD).

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable.

Fedwire Field Tag	Fedwire Field Name	Required Information
{1510}	Type/Subtype	<b>1000</b>
{2000}	Amount	<i>(enter payment amount)</i>
{3100}	Sender Bank ABA routing number	<i>(enter the US correspondent bank's ABA routing number)</i>
{3400}	Receiver ABA routing number*	<b>021030004</b>
{3400}	Receiver ABA short name	<b>TREAS NYC</b>
{3600}	Business Function Code	<b>CTR (or CTP)</b>
{4200}	Beneficiary Identifier (account number)**	<i>(enter 12 digit gateway account #)</i> <b>875080031006</b>
{4200}	Beneficiary Name	<i>(enter agency name associated with the Beneficiary Identifier)</i> <b>DHHS / NIH (75080031)</b>
{5000}	Originator	<i>(enter the name of the originator of the payment)</i> <b>COMPANY'S NAME</b>
{6000}	Originator to Beneficiary Information – Line 1	<i>(enter information to identify the purpose of the payment)</i> <b>ROYALTY</b>
{6000}	Originator to Beneficiary Information – Line 2	<i>(enter information to identify the purpose of the payment)</i> <b>LICENSE NUMBER</b>
{6000}	Originator to Beneficiary Information – Line 3	<i>(enter information to identify the purpose of the payment)</i> <b>INVOICE NUMBER</b>
{6000}	Originator to Beneficiary Information – Line 4	<i>(enter information to identify the purpose of the payment)</i>

Notes:

\*The financial institution address for Treasury's routing number is 33 Liberty Street, New York, NY 10045.

\*\*Anything other than the 12 digit gateway account # will cause the Fedwire to be returned – **SWIFT CODE:**

**FRNYUS33**

**Agency Contacts:**

Office of Technology Transfer (OTT) (301) 496-7057 [OTT-Royalties@mail.nih.gov](mailto:OTT-Royalties@mail.nih.gov)

**Checks**

A-XXX-201X

**CONFIDENTIAL**

NIH Biological Materials License Agreement (BMLA)

Model 10-2015 (updated 8-2012) Page 11 of 12 [Draft/Final] [Company] [Date]

All checks should be made payable to “NIH Patent Licensing”

Checks drawn on a **U.S. bank account** and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health  
P.O. Box 979071  
St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent by **overnight or courier** should be sent to the following address:

US Bank  
Government Lockbox SL-MO-C2GL  
1005 Convention Plaza  
St. Louis, MO 63101  
Phone: 314-418-4087

Checks drawn on a **foreign bank account** should be sent directly to the following address:

National Institutes of Health  
Office of Technology Transfer  
License Compliance and Administration  
Royalty Administration  
6011 Executive Boulevard  
Suite 325, MSC 7660  
Rockville, Maryland 20852

A-XXX-201X

**CONFIDENTIAL**

NIH Biological Materials License Agreement (BMLA)

Model 10-2015 (updated 8-2012) Page 12 of 12 [Draft/Final] [Company] [Date]